This is a working tumor board that covers active cases of patients with bone and soft tissue lesions associated with sarcoma (connective tissue neoplasms), metastatic carcinoma, and some metabolic bone disease. We discuss treatment plans/options/protocols for newly diagnosed and/or established adult musculoskeletal oncology patients based on the most up to date data/literature, evidence- based medicine, outcomes of our own research, and data accumulated at our tumor board via our ongoing data base. Discuss is had on treatment outcomes in comparison to the standard of care in evidence-based medicine and literature. Collaborate research efforts and establish research studies based on our findings and publish our outcomes. Continue to strengthen the multidisciplinary relationships that have evolved over the many years since this tumor board was established. It continues to grow as new treatment modalities that are founded/developed based on the on-going experience of the providers who are dedicated to attending our tumor board. These relationships continue to provide new collaborations, increase respect/trust, referrals, utilization of treatment resources and consistent continuity of care.
Keywords: sarcoma, connective tissue neoplasm, metastatic carcinoma, metabolic bone disease
Participants who engage in this educational intervention will be able to:
- Apply recent updates to treatment plans and protocols based on the discussions of the patient’s treatment at tumor board
- Expand our discussions to include the most recent and relevant literature evaluations on musculoskeletal oncology and disease protocols and treatment outcomes
- Continue to collaborate as a multidisciplinary unit to treat the patient as a whole and utilize treatment resources efficiently
- Publish research that is up to date and relevant to current literature
In accordance with the ACCME® Standards for Commercial Support Six, all in control of content must disclose any relevant financial relationships. The following in control of content had no relevant financial relationships to disclose.
- David King, MD
- Keith Baynes, MD
- Meena Bedi, MD
- Callisia Clarke, MD
- Melissa DuBois, MD
- John Logiudice, MD
- Rajeev Mannem,MD
- Reena Singh, MD
- Saul Suster, MD
- Matt Vickery, MD
- John Symanski, MD
- Lori Hollingsworth-Burds, PA-C
- Keenan Horness, PA-C
- Sean Veenendaal, PA-C
- Jennifer Merrill, NP
- Adam Wooldridge, MD, MPH
- Stephane Desouches, MD
- Nathan Schloemer, MD
- Sujan Fernando, MD
- Michael Stetz, MD
- Meghan Browning, MD
- Hesham Soliman, MD
- Blake Jones, MD
- Ross Cerniglia, MD
In accordance with the ACCME® Standards for Commercial Support Six, all in control of content must disclose any relevant financial relationships. These relationships were reviewed via the MCW conflict of interest resolution process and resolved.
|Sean Tutton, MD||Stryker||Consultant|
|Donald Hackbarth, MD||MTF Biologics||Board of Directors|
|John Neilson, MD||MTF Biologics||Board Member|
Brandon Rebholz, MD
|John Charlson, MD||Deciphera||Advisory Board|
|Peter Rossi, MD||Silk Road Medical||Consultant|
|Terumo Aortic||Speaker/ Consultant|
|Endospan||Data Safety Monitoring Board|
ACCME Accreditation Statement:
The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
AMA Credit Designation Statement:
The Medical College of Wisconsin designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Hours of Participation for Allied Health Care Professionals
The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.